Search Results - "Muss, H B"

Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review by Aleixo, G. F. P., Williams, G. R., Nyrop, K. A., Muss, H. B., Shachar, S. S.

“…Purpose Breast cancer is the most common cancer and leading cause of cancer death in women. Body composition parameters, especially those related to muscle,…”
Get full text

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence? by Nyrop, K. A., Williams, G. R., Muss, H. B., Shachar, S. S.

“…Most breast cancer (BC) tumors are early stage and hormone receptor positive, where treatment generally includes adjuvant endocrine treatment (ET). Oncology…”
Get full text

Association of body composition with function in women with early breast cancer by Aleixo, G. F. P., Deal, A. M., Nyrop, K. A., Muss, H. B., Damone, E. M., Williams, G. R., Yu, H., Shachar, S. S.

“…Background Advances in breast cancer research are making treatment options increasingly effective and reducing mortality. Body composition is an example of a…”
Get full text

Association of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer by Nyrop, KA, Page, A, Deal, AM, Wagoner, C, Kelly, EA, Kimmick, Gretchen G., Copeland, Anureet, Speca, JoEllen, Wood, William A., Muss, HB

“…Background In the field of exercise oncology, there is a need to quantify the potential benefits of moderate, self-directed physical activity during active…”
Get full text

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole by Goss, P.E., Ingle, J.N., Martino, S., Robert, N.J., Muss, H.B., Livingston, R.B., Davidson, N.E., Perez, E.A., Chavarri-Guerra, Y., Cameron, D.A., Pritchard, K.I., Whelan, T., Shepherd, L.E., Tu, D.

“…MA17 showed improved outcomes in postmenopausal women given extended letrozole (LET) after completing 5 years of adjuvant tamoxifen. Exploratory subgroup…”
Get full text

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840 by Lichtman, S.M., Hurria, A., Cirrincione, C.T., Seidman, A.D., Winer, E., Hudis, C., Cohen, H.J., Muss, H.B.

“…Two Cancer and Leukemia Group B (CALGB) studies were utilized to determine the efficacy and tolerability of paclitaxel (Taxol) in older patients with…”
Get full text

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) by Freedman, Rachel A., Seisler, D. K., Foster, J. C., Sloan, J. A., Lafky, J. M., Kimmick, G. G., Hurria, A., Cohen, H. J., Winer, E. P., Hudis, C. A., Partridge, A. H., Carey, L. A., Jatoi, A., Klepin, H. D., Citron, M., Berry, D. A., Shulman, L. N., Buzdar, A. U., Suman, V. J., Muss, H. B.

“…Purpose We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) events among 9679 women treated for breast cancer on four adjuvant Alliance…”
Get full text

Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907) by Ruddy, K.J., Pitcher, B.N., Archer, L.E., Cohen, H.J., Winer, E.P., Hudis, C.A., Muss, H.B., Partridge, A.H.

“…Cyclophosphamide-methotrexate-5-fluorouracil (CMF) is often selected as adjuvant chemotherapy for older patients with early-stage breast cancer due to…”
Get full text

Myosteatosis and prognosis in cancer: Systematic review and meta-analysis by Aleixo, G.F.P., Shachar, S.S., Nyrop, K.A., Muss, H.B., Malpica, Luis, Williams, G.R.

“…The evidence that body composition parameters influence multiple cancer outcomes is rapidly expanding. Excess adiposity deposits in muscle tissue, termed…”
Get full text

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 by Ingle, J. N., Tu, D., Pater, J. L., Muss, H. B., Martino, S., Robert, N. J., Piccart, M. J., Castiglione, M., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Cameron, D. A., Palmer, M. J., Goss, P. E.

“…Background: MA.17 evaluated letrozole or placebo after 5 years of tamoxifen and showed significant improvement in disease-free survival (DFS) for letrozole…”
Get full text

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer by Thor, Ann D., Berry, Donald A., Budman, Daniel R., Muss, Hyman B., Kute, Timothy, Henderson, I. Craig, Barcos, Maurice, Cirrincione, Constance, Edgerton, Susan, Allred, Craig, Norton, Larry, Liu, Edison T.

“…Background: We have previously reported that high expression of the erbB-2 gene (also known as HER-2/neu and ERBB2) in breast cancer is associated with patient…”
Get full text

American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines by SMITH, T. J, DAVIDSON, N. E, SCHAPIRA, D. V, GRUNFELD, E, MUSS, H. B, VOGEL, V. G, SOMERFIELD, M. R

“…To determine an effective, evidence-based, postoperative surveillance strategy for the detection and treatment of recurrent breast cancer. Tests are…”
Get full text

The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer by Aleixo, G. F. P., Shachar, S. S., Deal, A. M., Nyrop, K. A., Muss, H. B., Chen, Y. T., Yu, H., Williams, G. R.

“…Background Body composition metrics as predictors of adverse events are a growing area of interest in oncology research. One barrier to the use of these…”
Get full text

c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer by Muss, Hyman B, Thor, Ann D, Berry, Donald A, Kute, Timothy, Liu, Edison T, Koerner, Frederick, Cirrincione, Constance T, Budman, Daniel R, Wood, William C, Barcos, Maurice, Henderson, I. Craig

“…Several molecular markers have been associated with a poor prognosis in patients with breast cancer, and it is widely assumed that the presence of these…”
Get full text

Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer by Aleixo, G. F. P., Yu, H., Chen, Y. T., Nyrop, K. A., Louie, R. J., Deal, A. M., Shachar, S. S., Muss, H. B., Williams, G. R.

“…Background Myosteatosis (intramuscular adiposity) is predictive of chemotherapy toxicity in women undergoing adjuvant chemotherapy for breast cancer (BC). We…”
Get full text

Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer by Nyrop, K. A., Deal, A. M., Choi, S. K., Wagoner, C. W., Lee, J. T., Wood, A., Anders, C., Carey, L. A., Dees, E. C., Jolly, T. A., Reeder-Hayes, K. E., Muss, H. B.

“…Purpose Ensuring and measuring adherence to prescribed exercise regimens are fundamental challenges in intervention studies to promote exercise in adults with…”
Get full text

Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer by Nyrop, K. A., Damone, E. M., Deal, A. M., Wheeler, S. B., Charlot, M., Reeve, B. B., Basch, E., Shachar, S. S., Carey, L. A., Reeder-Hayes, K. E., Dees, E. C., Jolly, T. A., Kimmick, G. G., Karuturi, M. S., Reinbolt, R. E., Speca, J. C., Wood, W. A., Muss, H. B.

“…Purpose It is not known whether chemotherapy-related symptom experiences differ between Black and White women with early breast cancer (Stage I–III) receiving…”
Get full text

Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer by McQuellon, R P, Muss, H B, Hoffman, S L, Russell, G, Craven, B, Yellen, S B

“…The purpose of this study was to elicit preferences for the treatment of metastatic breast cancer in women with early-stage breast cancer who were given…”
Get more information

The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in Vermont by Lam, Prudence B., Vacek, Pamela M., Geller, Berta M., Muss, Hyman B.

“…BACKGROUND Etiologic studies of breast carcinoma have indicated that weight, body mass index (BMI), and breast tissue density are important determinants of a…”
Get full text

Recommendations for a Global Core Curriculum in Medical Oncology by Hansen, H. H., Bajorin, D. F., Muss, H. B., Purkalne, G., Schrijvers, D., Stahel, R.

Get full text